Alpha Cognition Launches Sales of Alzheimer’s Drug ZUNVEYL

Alpha Cognition Launches Sales of Alzheimer’s Drug ZUNVEYL

Dallas Innovates, Every Day: Here's what's new + next in North Texas. Last summer, Vancouver-based Alpha Cognition —a biopharmaceutical company with a North Texas office in Frisco—received FDA approval for its ZUNVEYL oral therapy to treat mild-to-moderate Alzheimer’s disease. Today marked the drug’s commercial launch,  ZUNVEYL, the brand name for benzgalantamine, is a next-generation acetylcholinesterase inhibitor approved in the U.S.…The post …

BioClec launches with backing from Sofinnova Partners to pioneer breakthrough Alzheimer’s Therapies – Optimum Strategic Communications

Co-founded by Dr. Marco Colonna, a global expert in neuroimmunology and Alzheimer’s research Led by CEO Gabriella Camboni, an eminent serial entrepreneur with a track record of successful biotech ventures MILAN, Italy – March 18, 2025 – BioClec, a cutting-edge biotechnology company focused on breakthrough therapies for Alzheimer’s disease (AD), announces its launch today. Emerging […]